Chemomab Therapeutics is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions that involve inflammation and fibrosis and have high unmet need. Fibrosis-related diseases are a significant unmet need that dramatically affect patients' health and quality of life.

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug, a monoclonal antibody that neutralizes CCL24 activity.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States.

2024年7月25日 · Chemomab's primary sclerosing cholangitis pitch fell flat with investors, who sent the biotech’s stock down around 18% when the market opened.

2025年3月3日 · Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 ...

2025年3月28日 · Get a real-time Chemomab Therapeutics Ltd. (CMMB) stock price with an overview of financials, statistics, forecasts, charts and more.

2019年2月8日 · 2021年3月16日，专注于发现和开发具有高度未满足需求的纤维化相关疾病的创新疗法的临床阶段的生物技术公司Chemomab Ltd.当天宣布完成与 Anchiano Therapeutics Ltd.的合并，合并后的公司将以Anchiano Therapeutics Ltd.之名运作，并启用新股票代码CMMB。

2025年2月19日 · Chemomab Therapeutics has announced that it has successfully completed its End-of-Phase 2 meeting with the FDA, aligning on the design of a single Phase 3 trial for its lead product candidate,...

Chemomab established strong preclinical evidence that demonstrates the potent anti-cholestatic and anti-fibrotic effects of nebokitug in PSC. Specifically: The overexpression of CCL24 and its correlation with fibrotic biomarkers was demonstrated …

2025年2月19日 · Chemomab's phase 3 trial for nebokitug in PSC aligns with FDA, focusing on clinical events without liver biopsies. Nebokitug, a monoclonal antibody, targets CCL24, disrupting inflammatory and fibrotic pathways in PSC. Previous trials, including SPRING, showed promising results, especially at higher doses, enhancing confidence in nebokitug's ...